IP Library › Granted Patent US 12,589,112
Granted Patent B2
US 12,589,112 · App. 17/794,913 · Granted Mar 31, 2026

Oncolytic virus compositions including IL-15 complex and methods for the treatment of cancer

Inventors: Jianhua Yu (Duarte, CA); Michael A. Caligiuri (Pasadena, CA)
Assignee: CITY OF HOPE
A61K35/17A61P35/00C07K14/5443C07K14/7155C12N7/00C12N15/62
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,589,112
App. No.
17/794,913
Granted
Mar 31, 2026
Kind
B2
Abstract

Provided herein, inter alia, are compositions and methods including recombinant oncolytic viruses expressing human IL-15 and human IL-15Rα-sushi domain for the treatment of cancer and immune disorders. The recombinant oncolytic viruses may be used in combination with immune cells expressing chimeric antigen receptors (CAR) targeting EGFR and EGFR mutants.

Claims (20)

1 . A recombinant oncolytic herpes simplex virus (HSV) comprising: an expression cassette comprising a nucleic acid encoding a human IL-15 domain and a nucleic acid encoding a human IL-15Rα sushi domain, wherein the nucleic acid encoding the human IL-15Rα sushi domain comprises SEQ ID NO:2.

2 . The recombinant oncolytic virus of claim 1 , wherein the expression cassette further comprises a nucleic acid encoding an IL-2 signal peptide sequence.

3 . The recombinant oncolytic virus of claim 1 , wherein the recombinant oncolytic virus does not comprise a nucleic acid encoding a γ34.5 gene or does not comprise a nucleic acid encoding a functional ICP6 gene.

4 . The recombinant oncolytic virus of claim 1 , wherein the nucleic acid encoding the IL-15 domain and the nucleic acid encoding the IL-15Rα sushi domain are under the control of a viral or tumor specific gene promoter.

5 . The recombinant oncolytic virus of claim 4 , wherein the nucleic acid encoding the IL-15 domain and the nucleic acid encoding the IL-15Rα sushi domain are under the control of herpes simplex virus (HSV) immediate early (IE) promoter.

6 . A pharmaceutical composition comprising: the recombinant oncolytic virus of claim 1 , and a pharmaceutically acceptable carrier.

7 . A combination therapy comprising the pharmaceutical composition of claim 6 and a checkpoint inhibitor.

8 . A method of treating a patient having cancer comprising administering to the patient an effective amount of the recombinant oncolytic virus of claim 1 .

9 . The method of claim 8 , wherein the cancer is selected from glioblastoma, ovarian cancer, pancreatic cancer, leukemia, myeloma, and lymphoma.

10 . A method of treating a subject with an overactive immune system or an autoimmune disease, comprising administering to the subject an effective amount of the recombinant oncolytic virus of claim 1 .

11 . A method for increasing cytotoxicity of natural killer (NK) cells and/or CD8 T cells in a subject, comprising administering an effective amount of the recombinant oncolytic virus of claim 1 .

12 . A method for increasing survival and/or proliferation of immune cells in a subject, comprising administering an effective amount the recombinant oncolytic virus of claim 1 .

13 . The method of claim 12 , wherein the immune cells are natural killer (NK) cells or CD8 T cells.

14 . A pharmaceutical composition comprising a first pharmaceutical dosage unit of the recombinant oncolytic virus of claim 1 , a second pharmaceutical dosage unit comprising Epidermal Growth Factor Receptor-Chimeric Antigen Receptor Natural Killer (EGFR-CAR NK) cells, and a pharmaceutically acceptable carrier.

15 . A combination therapy comprising the pharmaceutical composition of claim 14 and a checkpoint inhibitor.

16 . The method of claim 8 , further comprising administering to the patient an effective amount of an Epidermal Growth Factor Receptor-Chimeric Antigen Receptor Natural Killer (EGFR-CAR NK) cell.

17 . The method of claim 8 , further comprising administering to the patient a checkpoint inhibitor.

18 . The recombinant oncolytic virus of claim 1 , wherein the nucleic acid encoding the human IL15 domain comprises SEQ ID NO:1.

19 . The pharmaceutical composition of claim 14 , wherein the EGFR-CAR NK cells comprise an anti-EGFR antibody, wherein the anti-EGFR antibody comprises a variable light chain domain encoded by SEQ ID NO:7 and a variable heavy chain domain encoded by SEQ ID NO:8.

20 . A recombinant oncolytic herpes simplex virus (HSV) comprising: an expression cassette encoding a human IL15 domain and a human IL-15Rα sushi domain, wherein the expression cassette comprises SEQ ID NO:3.

Continuity (2)
Provisional Application 62964614 · Jan 22, 2020
Related Publication 20230147832A1 · May 11, 2023
References Cited (34)
US 7214515B2 · Chiocca et al. · 2007 [cited by applicant]
US 9862932B2 · Shah et al. · 2018 [cited by applicant]
US 10604574B2 · Evnin · 2020 [cited by applicant]
US 20020187163A1 · Johnson et al. · 2002 [cited by applicant]
US 20150250837A1 · Nolin et al. · 2015 [cited by applicant]
US 20160244740A1 · Kaur · 2016 [cited by applicant]
US 20170210811A1 · Wong et al. · 2017 [cited by applicant]
US 20180117146A1 · Yu · 2018 [cited by examiner]
US 20190048082A1 · Evnin · 2019 [cited by applicant]
US 20190169253A1 · Jia · 2019 [cited by examiner]
US 20200236916A1 · Shultz · 2020 [cited by examiner]
US 20230227549A1 · Yu et al. · 2023 [cited by applicant]
WO WO2008151182A2 · 2008 [cited by applicant]
WO WO2008151182A3 · 2008 [cited by applicant]
WO WO2019032866A1 · 2019 [cited by applicant]
WO WO2019129233A1 · 2019 [cited by applicant]
WO WO2020163721A1 · 2020 [cited by applicant]
WO WO2021159035A1 · 2021 [cited by applicant]
Chen et al. A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases. Oncotarget. Apr. 1, 2016; 7(19): 27764-27777. [cited by examiner]
Glorioso, J.C. et al. (2021, e-published Sep. 17, 2020). “Oncolytic HSV Vectors and Anti-Tumor Immunity,” [cited by applicant]
International Search Report mailed on Apr. 27, 2021 for PCT Application No. PCT/US2021/016973, filed Feb. 6, 2021, 3 pages. [cited by applicant]
International Search Report mailed on Jun. 4, 2021 for PCT Application No. PCT/US2021/014683, filed Jan. 22, 2021, 5 pages. [cited by applicant]
Written Opinion mailed on Apr. 27, 2021 for PCT Application No. PCT/US2021/016973, filed Feb. 6, 2021, 7 pages. [cited by applicant]
Written Opinion mailed on Jun. 4, 2021 for PCT Application No. PCT/US2021/014683, filed Jan. 22, 2021, 5 pages. [cited by applicant]
Barclay, A.N. et al. (2014, e-published Nov. 6, 2013). “The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target,” [cited by applicant]
Extended European Search Report mailed on Feb. 27, 2024, for EP Patent Application No. 21750415.8, 11 pages. [cited by applicant]
Huang, Y. et al. (Mar. 2020, e-published Feb. 7, 2020). “A SIRPα-Fc fusion protein enhances the antitumor effect of oncolytic adenovirus against ovarian cancer,” [cited by applicant]
Matlung, H.L. et al. (Mar. 4, 2017). “The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer,” [cited by applicant]
Passaro, C. et al. (Oct. 2, 2018). “Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy,” [cited by applicant]
Sivanandam, V. et al. (Apr. 25, 2019). “Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds,” [cited by applicant]
Xu, B. et al. (Oct. 8, 2021). “An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma,” [cited by applicant]
Drean, et al. (Dec. 2016, e-published Oct. 31, 2016). “PARP inhibitor combination therapy,” [cited by applicant]
Lee, N. et al. (Nov. 2016). “Upregulation of CD47 in Regulatory T Cells in Atopic Dermatitis,” [cited by applicant]
Lai, P.-K. et al. (Jan.-Dec. 2021). “Differences in human IgG1 and IgG4 S228P monoclonal antibodies viscosity and self-interactions: Experimental assessment and computational predictions of domain interactions,” [cited by applicant]